Related references
Note: Only part of the references are listed.The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
Christopher Southan et al.
NUCLEIC ACIDS RESEARCH (2016)
The EU is ready for non-biological complex medicinal products
Falk Ehmann et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2016)
THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Catalytic receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Enzymes
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13
Walter Reinisch et al.
Expert Review of Gastroenterology & Hepatology (2015)
Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women
Andreas Lammerich et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2015)
Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis
Sun Hyuk Hwang et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2014)
Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance
Fabrizio Cantini et al.
JOURNAL OF RHEUMATOLOGY (2014)
Epoetin Biosimilars in Europe: Five Years On
Ashraf Mikhail et al.
ADVANCES IN THERAPY (2013)
Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases
M. Rinaudo-Gaujous et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
John B. Warren
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Biosimilar recombinant human erythropoietins (epoetins) and future erythropoiesis-stimulating treatments
Wolfgang Jelkmann
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Presently available biosimilars in hematology-oncology: G-CSF
Pere Gascon
TARGETED ONCOLOGY (2012)
Development of a new G-CSF product based on biosimilarity assessment
P. Gascon et al.
ANNALS OF ONCOLOGY (2010)
Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency
Jan Regnstrom et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Development of BiosimilarsPharmacokinetic and Pharmacodynamic Considerations
Yow-Ming C. Wang et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2010)
Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa after Multiple Subcutaneous Administrations
Fritz Soergel et al.
PHARMACOLOGY (2009)
The first biosimilar epoetin: But how similar is it?
Huub Schellekens
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Biosimilar epoetins: An analysis based on recently implemented European medicines - Evaluation Agency guidelines on comparability of biopharmaceutical proteins
C Combe et al.
PHARMACOTHERAPY (2005)
Share Paper
